🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer

Recruitingn/aAges 18 Years - anyFemaleAbbVie
NCT07896421 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm. The goal of this observational study is to collect real-world data on treatment patterns, clinical effectiveness, participant characteristics, biomarker testing, and health-related quality of life in participants with FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer receiving mirvetuximab soravtansine. Mirvetuximab soravtansine (MIRV) is an approved antibody-drug conjugate being studied for the treatment of FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer. Adult participants with FRα-positive platinum-resistant cancer who have received 1-3 prior treatment lines and are scheduled to receive MIRV as monotherapy will be enrolled. Approximately 500 participants will be enrolled at sites globally.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Participants scheduled to be treated with mirvetuximab soravtansine in accordance with the local label, with treatment decision made independently before study enrollment * Signed informed consent and willingness to comply with study requirements including patient-reported outcome data collection Exclusion Criteria: * Any condition included in the contraindications section of the approved local mirvetuximab soravtansine label * Participation in a concurrent interventional clinical trial from enrollment throughout the study * Unwillingness or inability to comply with study requirements
💊

What it tests

  • Not listed
📍

Where

1 site
Medizinische Universitaet Wien /ID# 282657
Vienna, Austria
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy